Bio Path | BPTH - Selling And Administration Expenses

Stock Price
0.07
Daily Change
-0.004 -5.11%
Monthly
12.72%
Yearly
-63.27%
Q1 Forecast
0.07

Bio Path reported $1.26M in Selling and Administration Expenses for its fiscal quarter ending in March of 2025.





Selling And Administration Expenses Change Date
Alterity Therapeutics Limited AUD 2.29M 649.1K Jun/2023
Baxter International USD 761M 53M Dec/2025
Bio Path USD 1.26M 456K Mar/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.33M 50K Sep/2025
CSL USD 1.23B 498M Dec/2025
Grifols EUR 333.1M 157M Sep/2025
Karyopharm Therapeutics USD 27.19M 442K Dec/2024